CN108196061B - Double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibody - Google Patents
Double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibody Download PDFInfo
- Publication number
- CN108196061B CN108196061B CN201711367163.3A CN201711367163A CN108196061B CN 108196061 B CN108196061 B CN 108196061B CN 201711367163 A CN201711367163 A CN 201711367163A CN 108196061 B CN108196061 B CN 108196061B
- Authority
- CN
- China
- Prior art keywords
- add
- protein
- pgrn
- solution
- well
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101001027324 Homo sapiens Progranulin Proteins 0.000 title claims abstract description 38
- 238000003118 sandwich ELISA Methods 0.000 title claims abstract description 23
- 238000001514 detection method Methods 0.000 claims abstract description 45
- 239000000243 solution Substances 0.000 claims abstract description 41
- 238000002965 ELISA Methods 0.000 claims abstract description 38
- 239000011248 coating agent Substances 0.000 claims abstract description 33
- 238000000576 coating method Methods 0.000 claims abstract description 33
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 108090001008 Avidin Proteins 0.000 claims abstract description 29
- 229960002685 biotin Drugs 0.000 claims abstract description 26
- 239000011616 biotin Substances 0.000 claims abstract description 26
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 22
- 239000000758 substrate Substances 0.000 claims abstract description 16
- 239000012089 stop solution Substances 0.000 claims abstract description 13
- 238000005406 washing Methods 0.000 claims abstract description 12
- 235000020958 biotin Nutrition 0.000 claims abstract description 11
- 210000002966 serum Anatomy 0.000 claims abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 7
- 239000003085 diluting agent Substances 0.000 claims abstract description 5
- 101710114165 Progranulin Proteins 0.000 claims abstract 3
- 102100037632 Progranulin Human genes 0.000 claims abstract 3
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 22
- 230000000903 blocking effect Effects 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 7
- 239000012895 dilution Substances 0.000 claims description 7
- 230000000405 serological effect Effects 0.000 claims description 7
- 244000309466 calf Species 0.000 claims description 6
- 238000011161 development Methods 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 108020005004 Guide RNA Proteins 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002953 phosphate buffered saline Substances 0.000 claims description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 238000001742 protein purification Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 241000872931 Myoporum sandwicense Species 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 238000004445 quantitative analysis Methods 0.000 abstract description 2
- 102000006833 Multifunctional Enzymes Human genes 0.000 abstract 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 22
- 102000019204 Progranulins Human genes 0.000 description 20
- 108010012809 Progranulins Proteins 0.000 description 20
- 230000018109 developmental process Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000005457 optimization Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- GCSNAXXOAPCMDD-UHFFFAOYSA-N CC=1C=C(C=C(C1N)C)C1=CC(=C(N)C(=C1)C)C.CN(C1=CC=C(C2=CC=C(N(C)C)C=C2)C=C1)C Chemical compound CC=1C=C(C=C(C1N)C)C1=CC(=C(N)C(=C1)C)C.CN(C1=CC=C(C2=CC=C(N(C)C)C=C2)C=C1)C GCSNAXXOAPCMDD-UHFFFAOYSA-N 0.000 description 1
- 101100337798 Drosophila melanogaster grnd gene Proteins 0.000 description 1
- -1 GrnC Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明涉及生物技术和医学检测研究领域的试剂盒,具体涉及一种基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒。The invention relates to a kit in the fields of biotechnology and medical detection research, in particular to a double-sandwich ELISA kit for detecting human PGRN based on a monoclonal antibody.
背景技术Background technique
双夹心ELISA检测方法操作简单、高效、可靠、适用于大批样品快速筛选,基于单克隆抗体的双夹心ELISA较多克隆抗体更稳定,特异性更强。The double-sandwich ELISA detection method is simple, efficient, reliable, and suitable for rapid screening of a large number of samples. The double-sandwich ELISA based on monoclonal antibodies has more clonal antibodies, which are more stable and specific.
颗粒蛋白前体(Progranulin,PGRN)是一种含有593个氨基酸的分泌性糖蛋白,含有7.5个半胱氨酸结构域,命名为GrnP,GrnG,GrnF,GrnB,GrnA,GrnC,GrnD,GrnE。PGRN与胚胎发育,损伤修复,炎症,肿瘤的发生发展等生理病理过程息息相关。研究表明,人血清中PGRN的含量与一些疾病有关,如:糖尿病,肿瘤,神经退行性疾病等,PGRN作为一种分泌性糖蛋白,可以作为诊断这些相关疾病的标志物,对于这些疾病的诊断、治疗、监控及预后提供了重要的依据,所以快速、准确、高灵敏度地检测相关病人血清中的PGRN蛋白的含量尤为重要。Progranulin (PGRN) is a secreted glycoprotein containing 593 amino acids, containing 7.5 cysteine domains, named GrnP, GrnG, GrnF, GrnB, GrnA, GrnC, GrnD, GrnE. PGRN is closely related to physiological and pathological processes such as embryonic development, injury repair, inflammation, and tumor development. Studies have shown that the content of PGRN in human serum is related to some diseases, such as: diabetes, tumors, neurodegenerative diseases, etc. As a secreted glycoprotein, PGRN can be used as a marker for the diagnosis of these related diseases. , treatment, monitoring and prognosis provide an important basis, so it is particularly important to detect the content of PGRN protein in the serum of related patients quickly, accurately and with high sensitivity.
发明内容SUMMARY OF THE INVENTION
本发明的目的在于,提供一种简便、灵敏度高、特异性强、适应大规模检测的基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒。The purpose of the present invention is to provide a double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibody, which is simple, has high sensitivity, strong specificity and is suitable for large-scale detection.
为了实现上述任务,本发明通过以下技术方案得以实现:In order to realize the above-mentioned tasks, the present invention is realized through the following technical solutions:
一种基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒,其特征在于,该试剂盒的内容物组成如下:96孔ELISA酶标板、包被抗体4F10、人PGRN标准蛋白、生物素标记的检测抗体5B7-biotin、Avidin与HRP的交联蛋白、包被缓冲液、封闭液、样品及检测抗体稀释液、ELISA酶标板洗涤液、底物液和终止液。A double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibodies, characterized in that the contents of the kit are composed as follows: 96-hole ELISA plate, coating antibody 4F10, human PGRN standard protein, biotin-labeled Detection antibody 5B7-biotin, cross-linked protein of Avidin and HRP, coating buffer, blocking solution, sample and detection antibody dilution, ELISA plate washing solution, substrate solution and stop solution.
根据本发明,所述包被抗体4F10是针对人PGRN中GrnA结构域的小鼠抗人单克隆抗体,工作浓度为10μg/mL。According to the present invention, the coating antibody 4F10 is a mouse anti-human monoclonal antibody directed against the GrnA domain in human PGRN, and the working concentration is 10 μg/mL.
进一步地,所述生物素标记的检测抗体5B77-biotin是针对人PGRN中GrnB结构域的小鼠抗人单克隆抗体,工作稀释比例为1:4000。Further, the biotin-labeled detection antibody 5B77-biotin is a mouse anti-human monoclonal antibody against the GrnB domain in human PGRN, and the working dilution ratio is 1:4000.
所述的包被缓冲液为0.05M的碳酸盐缓冲液,pH为9.6;Described coating buffer is 0.05M carbonate buffer, pH is 9.6;
所述封闭液为含体积分数为10%小牛血清的磷酸盐缓冲液,pH为7.4;The blocking solution is a phosphate buffer containing 10% calf serum in volume fraction, and the pH is 7.4;
所述样品及检测抗体稀释液为含体积分数为1%小牛血清的磷酸盐缓冲液,pH为7.4;The sample and detection antibody diluent are phosphate buffered saline containing 1% calf serum, and the pH is 7.4;
所述ELISA酶标板洗涤液为含体积分数为0.1%Tween-20的磷酸盐缓冲液,pH为7.4;The ELISA plate washing solution is a phosphate buffer containing a volume fraction of 0.1% Tween-20, and the pH is 7.4;
所述底物液为TMB,即四甲基联苯胺(3,3’,5,5’-Tetramethylbenzidine)底物缓冲液;The substrate solution is TMB, namely tetramethylbenzidine (3,3',5,5'-Tetramethylbenzidine) substrate buffer;
所述终止液为摩尔浓度为2M的浓硫酸溶液。The stop solution is a concentrated sulfuric acid solution with a molar concentration of 2M.
所述人PGRN标准蛋白通过真核蛋白纯化的方法获得;所述Avidin与HRP的交联蛋白是采用过碘酸钠法将纯化的Avidin与HRP蛋白交联。The human PGRN standard protein is obtained by the method of eukaryotic protein purification; the cross-linked protein of Avidin and HRP is the cross-linking of purified Avidin and HRP protein by the sodium periodate method.
所述的过碘酸钠法是将HRP与过碘酸钠(NaIO4)反应,获得活化的HRP;The described sodium periodate method is to react HRP with sodium periodate (NaIO ) to obtain activated HRP;
所述的Avidin与活化的HRP反应,获得Avidin与HRP的交联蛋白。The Avidin reacts with activated HRP to obtain a cross-linked protein of Avidin and HRP.
根据申请人的试验表明,本发明的基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒,可以用于乳腺癌、肺癌及Ⅱ型糖尿病病人的血清学的检测应用。According to the test of the applicant, the double-sandwich ELISA kit for detecting human PGRN based on the monoclonal antibody of the present invention can be used for the serological detection application of breast cancer, lung cancer and type II diabetes patients.
所述乳腺癌、肺癌及Ⅱ型糖尿病病人的血清学的检测是检测重组的PGRN蛋白以及天然的人PGRN蛋白。The serological detection of the breast cancer, lung cancer and type II diabetes patients is to detect the recombinant PGRN protein and the natural human PGRN protein.
检测重组的PGRN蛋白以及天然的人PGRN蛋白具体包括以下步骤:The detection of recombinant PGRN protein and natural human PGRN protein specifically includes the following steps:
(1)包被ELISA酶标板:用包被缓冲液将包被抗体4F10稀释成10μg/mL,100μL/孔,4℃过夜;(1) Coating ELISA plate: Dilute the coating antibody 4F10 with coating buffer to 10 μg/mL, 100 μL/well, overnight at 4°C;
(2)封闭:甩去孔中液体,加入200μL/孔的ELISA酶标板洗涤液,洗涤3-5次后,加入200μL/孔的封闭液,37℃、2h后,洗涤3-5次,并甩干;(2) Blocking: shake off the liquid in the well, add 200 μL/well of ELISA plate washing solution, wash 3-5 times, add 200 μL/well of blocking solution, wash 3-5 times at 37°C for 2 hours, and spin dry;
(3)加待检测样品:向所述酶标板中加入待检测样品,100μL/孔,37℃、1h后,洗涤3-5次,并甩干;(3) Add the sample to be detected: add the sample to be detected to the ELISA plate, 100 μL/well, wash 3-5 times at 37°C for 1 hour, and spin dry;
(4)加检测抗体:向所述酶标板中加入5B7-biotin,100μL/孔,37℃、1h后,洗涤3-5次,并甩干;(4) Add detection antibody: add 5B7-biotin to the ELISA plate, 100 μL/well, wash 3-5 times at 37°C for 1 hour, and spin dry;
(5)加Avidin与HRP的交联蛋白:向所述酶标板中加入Avidin与HRP的交联蛋白,100μL/孔,37℃、1h后,洗涤5-6次,并甩干;(5) Add the cross-linked protein of Avidin and HRP: add the cross-linked protein of Avidin and HRP to the microtiter plate, 100 μL/well, wash 5-6 times at 37°C for 1 hour, and spin dry;
(6)显色:向所述酶标板中加入底物液,100μL/孔,37℃、3-5min。(6) Color development: Add substrate solution to the ELISA plate, 100 μL/well, 37° C., 3-5 min.
(7)终止:向所述酶标板中加入终止液,50μL/孔,反应后,酶标仪450nm处读数。(7) Stop: Add stop solution to the microplate plate, 50 μL/well, after the reaction, read at 450nm of the microplate reader.
本发明的基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒与现有技术相比,带来的有益技术效果在于:Compared with the prior art, the double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibody of the present invention has the following beneficial technical effects:
(1)所采用包被抗体和酶标抗体均为针对PGRN的单克隆抗体,较多克隆抗体更稳定,特异性更强;(1) The coated antibody and enzyme-labeled antibody used are both monoclonal antibodies against PGRN, and more cloned antibodies are more stable and specific;
(2)可快速检测癌症及糖尿病病人血清中的PGRN蛋白含量,由多功能酶标仪进行定量分析,结果准确可靠,为临床检验和基础研究提供了一种新的辅助工具。(2) The content of PGRN protein in the serum of cancer and diabetes patients can be quickly detected, and the quantitative analysis is carried out by a multi-function microplate reader. The results are accurate and reliable, and it provides a new auxiliary tool for clinical examination and basic research.
附图说明Description of drawings
图1是适用于检测人PGRN双夹心ELISA试剂盒的抗体最优配对筛选;Fig. 1 is the antibody optimal paired screening suitable for detecting human PGRN double-sandwich ELISA kit;
图2是基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒的优化;Fig. 2 is the optimization of the double-sandwich ELISA kit based on monoclonal antibody detection of human PGRN;
图3是基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒检测灵敏度的确定;Fig. 3 is the determination of the detection sensitivity of the double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibody;
图4是双夹心ELISA试剂盒检测不同人群血清中PGRN蛋白的结果,其中A图中,NGT为非糖尿病人群,T2D为Ⅱ型糖尿病病人,B图中,Breast cancer group为乳腺癌人群,lungcancer为肺癌人群,Health group为健康人对照。Figure 4 shows the results of double-sandwich ELISA kits for detecting PGRN protein in serum of different populations, in which, in panel A, NGT is a non-diabetic population, T2D is a type II diabetic patient, in panel B, Breast cancer group is a breast cancer population, lungcancer is a Lung cancer population, Health group as healthy controls.
以下结合附图和具体实施例对本发明做进一步详细说明。The present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.
具体实施方式Detailed ways
本实施例给出一种基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒。This example provides a double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibodies.
第一方面,采用单克隆抗体是运用杂交瘤细胞技术,通过人PGRN各个结构域Grns蛋白分别免疫小鼠,将免疫鼠的脾细胞与SP2/0骨髓瘤细胞融合,经过细胞克隆化与间接ELISA方法获得的11株针对人PGRN各个结构域的小鼠抗人单克隆抗体:4G3,2E2,1G6,4E8,5B7,4F10,2A5,3C5,3F9,1D5,3F7;再对11株单克隆抗体进行生物素(Biotin)标记,将包被抗体与酶标抗体分别进行双夹心抗体配对,筛选出最佳单克隆抗体配对:4F10(针对GrnAdomain)和5B7(针对GrnB domain)First, the use of monoclonal antibodies is to use hybridoma cell technology to immunize mice with Grns proteins in each domain of human PGRN, fuse the spleen cells of the immunized mice with SP2/0 myeloma cells, and undergo cell cloning and indirect ELISA. The obtained 11 mouse anti-human monoclonal antibodies against each domain of human PGRN: 4G3, 2E2, 1G6, 4E8, 5B7, 4F10, 2A5, 3C5, 3F9, 1D5, 3F7; Biotin labeling, the coating antibody and enzyme-labeled antibody were paired with double sandwich antibody respectively, and the best monoclonal antibody pairing was screened: 4F10 (for GrnA domain) and 5B7 (for GrnB domain)
第二方面,本实施例给出的基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒,该试剂盒的内容物组成如下:96孔ELISA酶标板、包被抗体4F10、人PGRN标准蛋白、生物素标记的检测抗体5B7-biotin、Avidin与HRP的交联蛋白、包被缓冲液、封闭液、样品及检测抗体稀释液、ELISA酶标板洗涤液、底物液和终止液。In the second aspect, the double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibodies provided in this example, the contents of the kit are composed as follows: 96-well ELISA plate, coating antibody 4F10, human PGRN standard protein, Biotin-labeled detection antibody 5B7-biotin, cross-linked protein of Avidin and HRP, coating buffer, blocking solution, sample and detection antibody diluent, ELISA plate washing solution, substrate solution and stop solution.
其中:in:
(1)包被抗体4F10的最优的抗体工作浓度为10μg/mL;(1) The optimal working concentration of the coated antibody 4F10 is 10 μg/mL;
(2)人PGRN标准蛋白,通过真核蛋白纯化的方法获得;(2) human PGRN standard protein, obtained by the method of eukaryotic protein purification;
(3)生物素标记的检测抗体5B7-biotin,通过生物素标记试剂盒(Thermo公司售)获得,工作最佳稀释比例:1:4000。(3) Biotin-labeled detection antibody 5B7-biotin, obtained by a biotin-labeling kit (sold by Thermo Company), the optimal dilution ratio for work: 1:4000.
(4)Avidin与HRP的交联蛋白,通过过碘酸钠法是HRP与过碘酸钠(NaIO4)反应,获得活化的HRP;Avidin与活化的HRP反应,获得Avidin与HRP的交联蛋白。(4) The cross-linked protein of Avidin and HRP, through the sodium periodate method, HRP reacts with sodium periodate (NaIO4) to obtain activated HRP; Avidin reacts with activated HRP to obtain the cross-linked protein of Avidin and HRP.
(5)包被缓冲液,0.05M的碳酸盐缓冲液(pH 9.6);(5) Coating buffer, 0.05M carbonate buffer (pH 9.6);
(6)封闭液,含体积分数为10%小牛血清的磷酸盐缓冲液(pH7.4);(6) Blocking solution, phosphate buffered saline (pH 7.4) containing 10% calf serum by volume;
(7)样品及检测抗体稀释液,含体积分数为1%小牛血清的磷酸盐缓冲液(pH7.4);(7) Sample and detection antibody diluent, phosphate buffered saline (pH 7.4) containing 1% calf serum by volume;
(8)ELISA酶标板洗涤液,含体积分数为0.1%Tween-20的PBS(PBST,pH7.4);(8) ELISA plate washing solution, containing PBS (PBST, pH 7.4) with a volume fraction of 0.1% Tween-20;
(9)底物液,含TMB的底物缓冲液;(9) substrate solution, substrate buffer containing TMB;
第三方面,本实施例给出的基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒,可以用于乳腺癌、肺癌及Ⅱ型糖尿病病人的血清学的检测应用。即检测重组的PGRN蛋白以及天然的人PGRN蛋白。In the third aspect, the double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibody provided in this example can be used for serological detection of breast cancer, lung cancer and type II diabetes patients. That is, the recombinant PGRN protein and the natural human PGRN protein are detected.
检测重组的PGRN蛋白以及天然的人PGRN蛋白具体包括以下步骤:The detection of recombinant PGRN protein and natural human PGRN protein specifically includes the following steps:
(1)包被ELISA酶标板:用包被缓冲液将包被抗体4F10稀释,100μL/孔,4℃过夜;(1) Coating ELISA plate: Dilute the coating antibody 4F10 with coating buffer, 100 μL/well, overnight at 4°C;
(2)封闭:甩去孔中液体,加入200μL/孔的ELISA酶标板洗涤液,洗涤3-5次后,加入200μL/孔的封闭液,37℃、2h后,洗涤3-5次,并甩干;(2) Blocking: shake off the liquid in the well, add 200 μL/well of ELISA plate washing solution, wash 3-5 times, add 200 μL/well of blocking solution, wash 3-5 times at 37°C for 2 hours, and spin dry;
(3)加待检测样品:向所述酶标板中加入待检测样品,100μL/孔,37℃、1h后,洗涤3-5次,并甩干;(3) Add the sample to be detected: add the sample to be detected to the ELISA plate, 100 μL/well, wash 3-5 times at 37°C for 1 hour, and spin dry;
(4)加检测抗体:向所述酶标板中加入5B7-biotin,100μL/孔,37℃、1h后,洗涤3-5次,并甩干;(4) Add detection antibody: add 5B7-biotin to the ELISA plate, 100 μL/well, wash 3-5 times at 37°C for 1 hour, and spin dry;
(5)加Avidin与HRP的交联蛋白:向所述酶标板中加入Avidin与HRP的交联蛋白,100μL/孔,37℃、1h后,洗涤5-6次,并甩干;(5) Add the cross-linked protein of Avidin and HRP: add the cross-linked protein of Avidin and HRP to the microtiter plate, 100 μL/well, wash 5-6 times at 37°C for 1 hour, and spin dry;
(6)显色:向所述酶标板中加入底物液,100μL/孔,37℃、3-5min。(6) Color development: Add substrate solution to the ELISA plate, 100 μL/well, 37° C., 3-5 min.
(7)终止:向所述酶标板中加入终止液,50μL/孔,反应后,酶标仪450nm处读数。(7) Stop: Add stop solution to the microplate plate, 50 μL/well, after the reaction, read at 450nm of the microplate reader.
以下是发明人给出的具体实施例,本发明并不限于以下的实施例。The following are specific examples given by the inventor, and the present invention is not limited to the following examples.
实施例1:双夹心ELISA抗体配对的筛选Example 1: Screening of double sandwich ELISA antibody pairings
(1)包被抗体:将纯化后的针对人PGRN各结构域的单克隆抗体anti-GrnG(4G3,2E2),anti-GrnF((1G6,4E8),anti-GrnB(5B7),anti-GrnA(4F10),anti-GrnC(2A5),anti-GrnD(3C5,3F9),anti-GrnE(1D5,3F7),稀释至10μg/mL,按照100μL/孔包被,4℃过夜;(1) Coating antibody: The purified monoclonal antibodies against each domain of human PGRN anti-GrnG (4G3, 2E2), anti-GrnF ((1G6, 4E8), anti-GrnB (5B7), anti-GrnA (4F10), anti-GrnC (2A5), anti-GrnD (3C5, 3F9), anti-GrnE (1D5, 3F7), diluted to 10 μg/mL, coated with 100 μL/well, overnight at 4°C;
(2)封闭:甩去孔中液体,加入200μL/孔的ELISA酶标板洗涤液,洗涤3-5次后,加入200μL/孔封闭液,37℃、2h后,洗涤3-5次,并甩干;(2) Blocking: shake off the liquid in the well, add 200 μL/well of ELISA plate washing solution, wash 3-5 times, add 200 μL/well blocking solution, wash 3-5 times at 37°C for 2 hours, and spin dry;
(3)加PGRN蛋白样品:向所述酶标板中加入PGRN蛋白样品(0.5μg/mL),100μL/孔,37℃、1h后,洗涤3-5次,并甩干;(3) Add PGRN protein sample: add PGRN protein sample (0.5 μg/mL) to the ELISA plate, 100 μL/well, wash 3-5 times at 37° C. for 1 h, and spin dry;
(4)加检测抗体:向所述酶标板中加入生物素标记的单克隆抗体,100μL/孔,37℃、1h后,洗涤3-5次,并甩干;(4) Add detection antibody: Add biotin-labeled monoclonal antibody to the ELISA plate, 100 μL/well, wash 3-5 times at 37°C for 1 hour, and spin dry;
(5)加Avidin与HRP的交联蛋白:向所述酶标板中加入Avidin与HRP的交联蛋白,100μL/孔,37℃、1h后,洗涤5-6次,并甩干;(5) Add the cross-linked protein of Avidin and HRP: add the cross-linked protein of Avidin and HRP to the microtiter plate, 100 μL/well, wash 5-6 times at 37°C for 1 hour, and spin dry;
(6)显色:向所述酶标板中加入底物液,100μL/孔,37℃、3-5min;(6) Color development: add substrate solution to the ELISA plate, 100 μL/well, 37°C, 3-5min;
(7)终止:向所述酶标板中加入终止液,50μL/孔,反应后,酶标仪450nm处读数。(7) Stop: Add stop solution to the microplate plate, 50 μL/well, after the reaction, read at 450nm of the microplate reader.
配对结果如图1所示,其中适用于检测人PGRN的双夹心ELISA试剂盒的最优配对抗体为:包被抗体4F10和生物素标记的检测抗体5B7-biotin。The pairing results are shown in Figure 1, wherein the optimal paired antibodies for the double-sandwich ELISA kit for detecting human PGRN are: the coated antibody 4F10 and the biotin-labeled detection antibody 5B7-biotin.
实施例2:Avidin与HRP蛋白交联Example 2: Cross-linking of Avidin to HRP protein
通过过碘酸钠法将Avidin与HRP进行交联,具体为:Avidin was cross-linked with HRP by the sodium periodate method, specifically:
首先HRP与过碘酸钠(NaIO4)反应,获得活化的HRP;Avidin与活化的HRP反应,获得Avidin与HRP的交联蛋白。First, HRP reacts with sodium periodate (NaIO4) to obtain activated HRP; Avidin reacts with activated HRP to obtain a cross-linked protein of Avidin and HRP.
实施例3:双夹心ELISA试剂盒优化Example 3: Optimization of Double Sandwich ELISA Kit
(1)包被抗体的优化(1) Optimization of coating antibodies
包被抗体选用针对GrnA的单克隆抗体4F10,将单克隆抗体4F10按照40μg/mL,20μg/mL,10μg/mL,5μg/mL,2.5μg/mL浓度梯度进行包被,封闭后,加入PGRN蛋白0.1μg/mL反应1h,将检测抗体5B7-Biotin加入检测孔中,37℃、1h后,洗涤3-5次,在反应孔中加入Avidin-HRP,37℃、1h后,洗涤5-6次,加入底物液进行显色,反应3-5min后将反应孔中加入终止液,于450nm处测量OD值。测量OD值减空白OD值最大的为较优的包被抗体浓度,结果如图2的A图所示,10μg/mL为最佳包被浓度。The monoclonal antibody 4F10 against GrnA was used as the coating antibody, and the monoclonal antibody 4F10 was coated with a concentration gradient of 40 μg/mL, 20 μg/mL, 10 μg/mL, 5 μg/mL, and 2.5 μg/mL. After blocking, PGRN protein was added. 0.1μg/mL reaction for 1h, add the detection antibody 5B7-Biotin to the detection well, wash 3-5 times after 1h at 37℃, add Avidin-HRP to the reaction well, wash 5-6 times after 37℃, 1h , add the substrate solution for color development, add stop solution to the reaction well after 3-5min reaction, and measure the OD value at 450nm. Measured OD value minus blank OD value is the best coating antibody concentration, the results are shown in Figure A of Figure 2, 10 μg/mL is the best coating concentration.
(2)检测抗体的优化(2) Optimization of detection antibodies
检测抗体选用针对GrnB单克隆抗体5B7,使用生物素(Biotin)对5B7抗体进行标记,获得5B7-Biotin。对检测抗体Biotin-5B7的浓度进行优化,将Biotin-5B7按照1/250、1/1000、1/2000、1/4000、1/8000、1/16000、1/32000进行梯度稀释,按照上述方法进行检测。选择测量OD值最大同时检测抗体最低浓度为最佳稀释浓度,结果如图2的B图所示,1/4000为最佳稀释浓度。The detection antibody is the monoclonal antibody 5B7 against GrnB, and the 5B7 antibody is labeled with biotin to obtain 5B7-Biotin. The concentration of the detection antibody Biotin-5B7 was optimized, and Biotin-5B7 was serially diluted according to 1/250, 1/1000, 1/2000, 1/4000, 1/8000, 1/16000, 1/32000, according to the above method. test. The optimal dilution concentration is selected to measure the maximum OD value and the lowest concentration of the detection antibody. The results are shown in Figure B of Figure 2, and 1/4000 is the optimal dilution concentration.
(3)检测灵敏度的确定(3) Determination of detection sensitivity
使用优化的包被抗体浓度包被、封闭后,加入梯度稀释的PGRN真核表达蛋白,37℃、1h后,洗涤3-5次,在待测孔中5B7-Biotin检测抗体(1:4000),37℃、1h后,洗涤3-5次,分别加入Avidin-HRP交联蛋白,37℃、1h后,洗涤5-6次,再加入底物液进行反应,于450nm处测量,结果如图3所示,可检测灵敏度为125pg/mL-63pg/mL,可检测到的范围为8ng/mL-125pg/mL。After coating and blocking with the optimized coating antibody concentration, add the PGRN eukaryotic expression protein diluted in gradient, wash 3-5 times at 37°C for 1 h, and detect the antibody (1:4000) in 5B7-Biotin in the well to be tested. , after 37℃, 1h, wash 3-5 times, add Avidin-HRP cross-linked protein respectively, after 37℃, 1h, wash 5-6 times, then add substrate solution for reaction, measure at 450nm, the results are shown in the figure 3, the detectable sensitivity is 125pg/mL-63pg/mL, and the detectable range is 8ng/mL-125pg/mL.
实施例5:基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒的检测方法Embodiment 5: Detection method of double sandwich ELISA kit based on monoclonal antibody detection of human PGRN
(1)包被ELISA酶标板:包被缓冲液将包被抗体4F10稀释成10μg/mL,100μL/孔,4℃过夜;(1) Coating ELISA plate: Dilute the coating antibody 4F10 to 10 μg/mL in coating buffer, 100 μL/well, overnight at 4°C;
(2)封闭:甩去孔中液体,加入200μL/孔的ELISA酶标板洗涤液,洗涤3-5次后,加入200μL/孔的封闭液,37℃、2h后,洗涤3-5次,并甩干;(2) Blocking: shake off the liquid in the well, add 200 μL/well of ELISA plate washing solution, wash 3-5 times, add 200 μL/well of blocking solution, wash 3-5 times at 37°C for 2 hours, and spin dry;
(3)加待检测样品:将待测样品进行适当稀释,加入所述的酶标板中,100μL/孔,37℃、1h后,洗涤3-5次,并甩干;(3) Add the sample to be tested: Dilute the sample to be tested appropriately, add it to the ELISA plate, 100 μL/well, 37°C for 1 h, wash 3-5 times, and spin dry;
(4)加检测抗体:向所述酶标板中加入5B7-biotin,100μL/孔,37℃、1-2h后,洗涤3-5次,并甩干;(4) Add detection antibody: add 5B7-biotin to the ELISA plate, 100 μL/well, wash 3-5 times at 37°C for 1-2 hours, and spin dry;
(5)加Avidin与HRP的交联蛋白:向所述酶标板中加入Avidin与HRP的交联蛋白,100μL/孔,37℃、1h后,洗涤5-6次,并甩干;(5) Add the cross-linked protein of Avidin and HRP: add the cross-linked protein of Avidin and HRP to the microtiter plate, 100 μL/well, wash 5-6 times at 37°C for 1 hour, and spin dry;
(6))显色:向所述酶标板中加入底物液,100μL/孔,37℃、3-5min;(6)) Color development: add substrate solution to the ELISA plate, 100 μL/well, 37°C, 3-5min;
(7)终止:向所述酶标板中加入终止液,50μL/孔,反应后,酶标仪450nm处读数。(7) Termination: Add stop solution to the microtiter plate, 50 μL/well, after the reaction, read at 450nm of the microplate reader.
实施例6:基于单克隆抗体检测人PGRN的双夹心ELISA试剂盒的应用Example 6: Application of double-sandwich ELISA kit for detection of human PGRN based on monoclonal antibody
用实施例5建立的ELISA方法检测30例癌症病人(样本来源于山西省汾阳医院,其中23例肺癌,7例乳腺癌)和30例正常健康人群(健康人群选自陕西师范大学学生体检样本);205例Ⅱ型糖尿病病人(样本来源于南京第一人民医院)和78例正常健康人群(健康人群选自陕西师范大学学生体检样本),将PGRN重组蛋白作为阳性对照,根据所得标准品OD值与所对应浓度绘制标准曲线,计算各人群中PGRN蛋白的血清学水平。The ELISA method established in Example 5 was used to detect 30 cases of cancer patients (samples from Fenyang Hospital in Shanxi Province, including 23 cases of lung cancer and 7 cases of breast cancer) and 30 cases of normal healthy people (healthy people were selected from the physical examination samples of students from Shaanxi Normal University) ); 205 patients with type Ⅱ diabetes (samples were from Nanjing First People’s Hospital) and 78 normal healthy people (healthy people were selected from the physical examination samples of students from Shaanxi Normal University), PGRN recombinant protein was used as a positive control, according to the obtained standard OD A standard curve was drawn between the values and the corresponding concentrations, and the serological levels of PGRN protein in each population were calculated.
结果如图4所示,乳腺癌、肺癌及糖尿病症组人群PGRN蛋白的血清学水平明显高于正常人,差异有统计学意义(p<0.001)。Results As shown in Figure 4, the serological levels of PGRN protein in the breast cancer, lung cancer and diabetes groups were significantly higher than those in the normal people, and the difference was statistically significant (p<0.001).
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711367163.3A CN108196061B (en) | 2017-12-18 | 2017-12-18 | Double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711367163.3A CN108196061B (en) | 2017-12-18 | 2017-12-18 | Double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108196061A CN108196061A (en) | 2018-06-22 |
CN108196061B true CN108196061B (en) | 2020-08-28 |
Family
ID=62574547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711367163.3A Expired - Fee Related CN108196061B (en) | 2017-12-18 | 2017-12-18 | Double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibody |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108196061B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108982858B (en) * | 2018-07-05 | 2021-06-15 | 陕西师范大学 | A double-sandwich ELISA kit for detection of human proGRP based on monoclonal antibody |
US20230194508A1 (en) * | 2020-05-21 | 2023-06-22 | The Chinese University Of Hong Kong | Thermodynamically stabilized antibodies for deep immunolabeling and tissue imaging |
CN119156399A (en) * | 2022-02-24 | 2024-12-17 | A&G 药品公司 | Fully human monoclonal antibodies against human granulin precursors |
CN115112903B (en) * | 2022-07-11 | 2024-12-24 | 重庆医科大学 | Application of progranulin in the diagnosis, prognosis and treatment of invasive Candida infection |
-
2017
- 2017-12-18 CN CN201711367163.3A patent/CN108196061B/en not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
Autocrine growth factor revisited: PC-cell-derived growth factor (progranulin), a critical player in breast cancer tumorigenesis;Ginette Serrero;《Biochemical and Biophysical Research Communications》;20030829;第308卷(第3期);摘要 * |
Domain-Specific Monoclonal Antibodies Produced Against Human PGRN;Lihong Chai et al;《HYBRIDOMA》;20111231;第30卷(第3期);摘要,Table 1, Fig 5-6 * |
GP88 (progranulin): a novel tissue and circulating biomarker for non–small cell lung carcinoma;Martin J.Edelman et al;《Human Pathology》;20140605;第45卷(第9期);摘要 * |
Serum Progranulin Concentrations May Be Associated With Macrophage Infiltration Into Omental Adipose Tissue;Byung-Soo Youn et al;《Diabetes》;20090331;第58卷(第3期);摘要 * |
Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity;Atsushi Tanaka et al;《Arthritis Research & Therapy》;20121231;第14卷;摘要,第3页左栏最后一段 * |
Also Published As
Publication number | Publication date |
---|---|
CN108196061A (en) | 2018-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017107974A1 (en) | Detection test kit for serum psmd4 proteins and detection method and application thereof | |
CN108196061B (en) | Double-sandwich ELISA kit for detecting human PGRN based on monoclonal antibody | |
JP5555846B2 (en) | Prognosis determination method for acute central nervous system disorder | |
ES2560559T3 (en) | Monoclonal antibody to analyze high molecular weight adiponectin and its use | |
CN111638332A (en) | Novel coronavirus IgA/IgM/IgG antibody ELISA detection kit | |
CN101672851B (en) | Preparation of Human Tissue Kallikrein ELISA Kit | |
ATE474855T1 (en) | POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTION OF N-TERMINAL PROBNP | |
CN104678110A (en) | Serum CENPF antibody quantitative detection kit | |
CN102138072B (en) | Diagnosis method and diagnosis kit for dermatomyositis | |
CN118063608B (en) | Monoclonal antibody for triiodothyronine, detection reagent based on monoclonal antibody and application of monoclonal antibody | |
CN118772273A (en) | A testosterone sandwich rabbit monoclonal antibody mAb1 and its application | |
CN106153934A (en) | A kind of test kit of efficient quantitative detection Golgi body 73 | |
CN109503713A (en) | Anti-human SAA monoclonal antibody and its preparation method and application | |
CN111398600A (en) | E L ISA detection kit of human soluble BCMA protein and use method and application thereof | |
CN103833859B (en) | New type of S mith chimeric peptide antigen and the application in laboratory diagnosis thereof | |
CN107746430B (en) | Preparation and application of GP 73C-terminal antigen | |
CN117777286A (en) | Antibody A4D7 targeting procalcitonin and application thereof | |
CN206638678U (en) | Multi objective time-resolved fluoroimmunoassay for postoperative patient monitoring chromatographs kit | |
IL263517B2 (en) | Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis | |
CN108535494A (en) | A kind of IL-6ELISA detection kits and its application method | |
KR101893244B1 (en) | Novel Biomarker Indicative of Diabetes and Their Uses | |
JP5857385B2 (en) | Bladder cancer diagnostic composition containing APE1 / REF-1 and bladder cancer diagnostic kit using the same | |
CN110716054A (en) | A kit for quantitative detection of serum cytophilic immunoglobulin E | |
CN110068676A (en) | Application of the secretory protein Serpin A3 in prediction diagnosis of myocardial damage reagent | |
CN108957013A (en) | IGLON5 and SERPINB13 albumen relevant to osteoarthritis and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200828 |
|
CF01 | Termination of patent right due to non-payment of annual fee |